Myasthenia Gravis

🧠 Standard of Care & Symptoms

Myasthenia Gravis (MG) is a chronic, autoimmune, neuromuscular disorder characterized by fluctuating skeletal muscle weakness that worsens with activity and improves with rest.

• Presentation: Key cutaneous features.
  • *Ocular Weakness:* drooped eyelids (**ptosis**) and double vision (**diplopia**). Ocular signs are the initial presentation in over 50% of patients.
  • *Bulbar Dysfunction:* Weakness of facial expression muscles, difficulty chewing (masticatory fatigue), slurred nasal speech (**dysarthria**), and difficulty swallowing (**dysphagia**), which increases aspiration risk.
  • *Limb & Trunk Weakness:* Fluctuating weakness typically affecting proximal limb muscles (e.g., difficulty climbing stairs or brushing hair).
  • *Myasthenic Crisis:* A life-threatening emergency characterized by severe weakness of the diaphragm and intercostal respiratory muscles, leading to acute respiratory failure requiring mechanical ventilation.

🧬 Diagnostics & NMJ Pathophysiology

Diagnosis is established through serum antibody testing, electrodiagnostic studies, and pharmacological challenge tests.

• Diagnostic Testing: Key pathways.
  • Antibody Assays: Serum **Acetylcholine Receptor (AChR) antibodies** are present in 85% of generalized MG patients. **Muscle-Specific Kinase (MuSK) antibodies** are present in 10-20% of AChR-seronegative patients. LRP4 antibodies are tested in double-seronegative cases.
  • Electrodiagnostics: Repetitive Nerve Stimulation (RNS) shows a decremental response (>10% drop in amplitude). Single-Fiber Electromyography (SFEMG) shows increased jitter and block, representing the most sensitive test.
  • Pharmacological Test: Intravenous Edrophonium (Tensilon) test, which temporarily blocks acetylcholinesterase, leading to rapid, brief improvement in muscle weakness (rarely used due to cardiac risks).

Pathophysiology of Neuromuscular Junction (NMJ) Failure

The hallmark muscle fatigability in MG is caused by antibody-mediated destruction of postsynaptic acetylcholine receptors:

• Receptor Blocking & Cross-Linking: Autoantibodies bind to the extracellular domain of the **postsynaptic Acetylcholine Receptors (AChRs)**. They physically block acetylcholine binding and trigger receptor endocytosis via cross-linking.
• Complement Activation: The bound antibodies activate the classical complement pathway, depositing the **Membrane Attack Complex (MAC)**. This causes structural damage, flattening the postsynaptic membrane folds and widening the synaptic cleft.
• Transmission Failure: Due to receptor loss and architectural flattening, acetylcholine binding cannot trigger a sufficient end-plate potential (EPP) to exceed the threshold for action potential generation, resulting in muscle weakness and fatigability.

💊 Immunosuppressants, FcRn Blockers & Thymectomy

Therapy targets both symptomatic improvement and long-term immunosuppression to reduce pathogenic antibody levels.

First-Line Symptomatic Treatment

• Acetylcholinesterase Inhibitors: Oral **Pyridostigmine Bromide** (Mestinon) is the first-line therapy. It inhibits the enzyme acetylcholinesterase, preventing acetylcholine degradation and prolonging its availability in the synaptic cleft.

Immunosuppressants & Advanced Biologics

• Corticosteroids & Steroid-Sparing Agents: Oral Prednisone is used for rapid immunosuppression. Long-term maintenance uses steroid-sparing agents like **Azathioprine** or **Mycophenolate Mofetil**.
• FcRn Blockers: **Efgartigimod** (Vyvgart) blocks the neonatal Fc receptor (FcRn), preventing IgG recycling and driving rapid degradation of circulating pathogenic AChR/MuSK autoantibodies.
• Complement Inhibitors: **Eculizumab** (Soliris) or Ravulizumab block C5 complement activation, preventing MAC-mediated damage at the postsynaptic membrane.

Surgical & Crisis Care

• Thymectomy: Surgical removal of the thymus gland is recommended for all patients with thymoma and is highly beneficial in non-thymomatous, generalized AChR-positive patients under age 50 to induce remission.
• Crisis Management: Plasma Exchange (Plasmapheresis) or Intravenous Immunoglobulin (IVIG) are utilized for rapid clearance of antibodies during a myasthenic crisis.

🔬 Active Clinical Trials

Clinical trials are currently evaluating subcutaneous FcRn blockers, selective complement inhibitors, and CAR-T cell therapies targeting autoantibody-producing B-cells.

🗺️ Next Steps After Diagnosis

If you have recently been diagnosed with Myasthenia Gravis, establish these clinical care pathways:

1. Confirm Antibody Status: Ensure your blood tests check for both AChR and MuSK antibodies to identify your sub-type.
2. Perform Chest CT Scan: Undergo a chest CT scan to screen for **thymoma** (thymic tumor) or thymic hyperplasia.
3. Establish Pyridostigmine Schedule: Work with your neurologist to optimize the timing of Pyridostigmine to maximize strength during meals.
4. Avoid Trigger Medications: Familiarize yourself with contraindicated drugs that can trigger muscle weakness (e.g. fluoroquinolones, beta-blockers, magnesium).

❓ Patient FAQ

Q: What is the difference between AChR-positive and MuSK-positive Myasthenia Gravis?
A: AChR-positive MG is the most common form, often associated with thymic abnormalities and responding well to Pyridostigmine and thymectomy. MuSK-positive MG typically presents with more severe bulbar and respiratory weakness, rarely involves thymoma (so thymectomy is not indicated), is often refractory to Pyridostigmine (which can worsen MuSK symptoms), and responds exceptionally well to Rituximab.

Q: What are the signs of a Myasthenic Crisis?
A: Warning signs include progressive difficulty swallowing (choking on liquids), slurred speech, shortness of breath at rest, and orthopnea (difficulty breathing while lying flat). If these signs occur, seek emergency medical care immediately.